Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Publication year range
1.
Front Cell Dev Biol ; 9: 740267, 2021.
Article in English | MEDLINE | ID: mdl-34497810

ABSTRACT

Thyroid cancer ranks second in the incidence rate of endocrine malignant cancer. Thyroid cancer is usually asymptomatic at the initial stage, which makes patients easily miss the early treatment time. Combining genetic testing with imaging can greatly improve the diagnostic efficiency of thyroid cancer. Researchers have discovered many genes related to thyroid cancer. However, the effects of these genes on thyroid cancer are different. We hypothesize that there is a stronger interaction between the core genes that cause thyroid cancer. Based on this hypothesis, we constructed an interaction network of thyroid cancer-related genes. We traversed the network through random walks, and sorted thyroid cancer-related genes through ADNN which is fusion of Adaboost and deep neural network (DNN). In addition, we discovered more thyroid cancer-related genes by ADNN. In order to verify the accuracy of ADNN, we conducted a fivefold cross-validation. ADNN achieved AUC of 0.85 and AUPR of 0.81, which are more accurate than other methods.

2.
Nan Fang Yi Ke Da Xue Xue Bao ; 28(5): 839-42, 2008 May.
Article in Chinese | MEDLINE | ID: mdl-18504215

ABSTRACT

OBJECTIVE: To compare the therapeutic effect of recombinant human brain natriuretic peptide (rhBNP) and nitroglycerin on acute decompensated heart failure (ADHF). METHODS: Fifty ADHF patients were randomly divided into rhBNP group and nitroglycerin group. In all the patients, dyspnea and global clinical status were assessed before and at 30 min, 6 h and 24 h after drug administration, and the volume of fluid intake and urine along with hemodynamic parameters was recorded 24 h after drug administration. In the nitroglycerin group, the patients received an initial nitroglycerin dose of 5 microg/min, with subsequent dose increment of 5 microg/min every 3 to 5 min; the dose was adjusted individually according to the hemodynamics of the patients. The patients in rhBNP group were given rhBNP at the initial dose of 1.5 microg/kg by with an intravenous bolus injection followed by infusion at the rate of 0.0075 microg.kg(-1).min(-1) for 72 h. RESULTS: At 30 min and 6 h after drug administration, the patients in the rhBNP group showed significant greater improvement of dyspnea (P=0.042 and 0.019) and global clinical status (P=0.018 and 0.044) than those in the nitroglycerin group, but 24 h after drug administration, no significant difference was noted between the two groups (P=0.192 and 0.179). Twenty-four hours after drug administration, the mean urine volume was significantly greater in rhBNP group than in nitroglycerin group (1513.8-/+242.9 vs 1341.2-/+239.7 ml, P=0.015), and the ejection fraction increased and pulmonary arterial pressure and systolic blood pressure decreased at greater amplitude in the former group (P=0.001,0.000 and 0.002, respectively). At 72 h, the numbers of premature ventricular contraction and couplets premature beats and onset of paroxysmal ventricular tachycardia were significantly reduced in rhBNP group as compared with the nitroglycerin group (P=0, 0.001 and 0.002, respectively). CONCLUSION: RhBNP promotes urine excretion, decreases pulmonary arterial pressure and increases left ventricular ejection fraction to improve dyspnea and global clinical status and reduce the onset of ventricular arrhythmia in ADHF patients.


Subject(s)
Heart Failure/drug therapy , Natriuretic Peptide, Brain/therapeutic use , Aged , Aged, 80 and over , Blood Pressure/drug effects , Female , Heart Failure/pathology , Heart Failure/physiopathology , Humans , Infusions, Intravenous , Male , Middle Aged , Natriuretic Peptide, Brain/administration & dosage , Natriuretic Peptide, Brain/genetics , Nitric Oxide Donors/administration & dosage , Nitric Oxide Donors/therapeutic use , Nitroglycerin/administration & dosage , Nitroglycerin/therapeutic use , Recombinant Proteins/administration & dosage , Recombinant Proteins/therapeutic use , Treatment Outcome
3.
Nan Fang Yi Ke Da Xue Xue Bao ; 28(4): 542-4, 2008 Apr.
Article in Chinese | MEDLINE | ID: mdl-18495585

ABSTRACT

OBJECTIVE: To investigate the effects of ultrasound mediated microbubble destruction on capillary permeability in rat skeletal muscles. METHODS: Eighteen SD rats were randomized into 3 groups, namely the Evans blue (EB) group, EB+ultrasound (E+U) group and EB+microbubble+ultrasound (U+E+M) group with corresponding treatments, using EB injected into the carotid artery as the indicator for capillary permeability. The microbubbles were injected through the carotid artery with fixed ultrasound parameters. The spillover of EB was estimated under fluorescence microscope according to the visual staining scores. The contents of EB in the skeletal muscles were calculated according to the standard curve and spectrophotometry. RESULTS: EB spillover was observed around the capillaries in E+U+M group, which had a significantly higher visual score than EB group and E+U group (0 and 0-1, respectively, P<0.05). The EB content was 51.57-/+3.89 microg/g in E+U+M group, also significantly higher than those in EB group (28.99-/+4.67 microg/g) and E+U group (30.99-/+4.11 microg/g) (P<0.05). CONCLUSION: Exposure to both ultrasound and microbubble contrast agents results in increased capillary permeability of rat skeletal muscles, which might be an important mechanisms for gene delivery enhancement by ultrasound contrast agents.


Subject(s)
Capillary Permeability/physiology , Microbubbles , Muscle, Skeletal/blood supply , Ultrasonics , Animals , Coloring Agents/administration & dosage , Coloring Agents/pharmacokinetics , Contrast Media/administration & dosage , Evans Blue/administration & dosage , Evans Blue/pharmacokinetics , Female , Male , Microscopy, Fluorescence , Muscle, Skeletal/metabolism , Random Allocation , Rats , Rats, Sprague-Dawley , Spectrophotometry
4.
Zhonghua Yi Xue Za Zhi ; 87(16): 1136-8, 2007 Apr 24.
Article in Chinese | MEDLINE | ID: mdl-17673000

ABSTRACT

OBJECTIVE: To investigate the optimal atrioventricular delay (AVD) in using dual-chamber pacemaker. METHODS: Thirty patients with atrioventricular conduction block, aged 62 +/- 12, implanted for were implanted with DDD pacemakers. Program controller was used to program the AVD. Two-dimensional echocardiography was used to measure the hemodynamic parameters: cardiac output (CO), cardiac output index (CI), stroke volume (SV), left ventricular ejection fraction (LVEF), left ventricular end-systolic diameter (LVESd), left ventricular end-diastolic diameter (LVEDd), peak systolic velocity (Vs), and peak systolic time of the basic segment at inter-ventricular septum and left ventricular under the pattern of tissue velocity imaging at different values of AVD. For each patient, the AVD was prolonged to 250 ms stepwise by 30 ms starting from 100 ms. RESULTS: Cardiac function changed with different AVD. When the AVD was 160 ms, the maximal values were reached for CO (5.5 L/min+/-1.1 L/min, P<0.05), CI (3.5 Lxmin(-1)xm(-2)+/-0.8 Lxmin(-1)xm(-2), P<0.05), SV (78 ml+/-13 ml, P<0.05), LVEF (67%+/-7%, P<0.05), LVEDd (121 mm+/-29 mm, P<0.05), and Vs. LVESd reached its minimal value (37 mm+/-16 mm, P<0.05) and the Vs values of different ventricular walls reached the minimal too (all P<0.05). CONCLUSION: When the optimal AVD is selected the cardiac function can be significantly improved. Tissue Doppler echocardiography is useful in evaluating cardiac function and determining the optimal AVD.


Subject(s)
Cardiac Pacing, Artificial , Heart Block/physiopathology , Heart Block/therapy , Adult , Aged , Aged, 80 and over , Echocardiography, Doppler , Female , Follow-Up Studies , Heart Block/diagnostic imaging , Humans , Male , Middle Aged
SELECTION OF CITATIONS
SEARCH DETAIL
...